ShockWave Medical Stock - Weekly analyst views after Boston Scientific deal
17.06.2026 - 18:50:01 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 16:45 UTC. Details in the imprint.
ShockWave Medical (US8130281086) sits in the middle of a multi-billion dollar takeover by Boston Scientific. The transaction, announced in April, still shapes analyst discussion this week, according to a Reuters report on the deal.
All news and analysis on ShockWave Medical stock
Key filings, deal terms and market data on ShockWave Medical are bundled in our topic overview.
What the Boston deal entails
Boston Scientific agreed on 04/05/2024 to acquire ShockWave Medical in a cash transaction valuing the company at about $13.8 billion, including debt, or $335 per share. Reuters cites the definitive agreement and notes expected closing by late 2024, subject to approvals.
In its own communication, Boston Scientific described ShockWave’s intravascular lithotripsy technology as a strategic fit to strengthen its cardiovascular portfolio. The company expects the acquisition to be slightly dilutive to adjusted earnings per share in the first year after closing, then accretive thereafter.
How analysts frame valuation now
Since the deal announcement, analyst research has largely shifted from traditional earnings-based valuation to merger-arbitrage perspectives around the $335 offer price. According to MarketWatch data, several houses now reference the agreed cash consideration as their effective target level.
Spread between the current trading price and the offer tends to reflect regulatory timing, deal-completion risk and alternative-return considerations, not a stand-alone view on ShockWave’s long-term fundamentals. That is typical once a definitive all-cash takeover is in place.
Consensus and rating landscape
Before the takeover, a majority of analysts rated ShockWave Medical as Buy or Overweight, citing structural demand in coronary and peripheral artery disease. Consensus 2024 revenue expectations had pointed to robust double-digit growth from a roughly $730 million base in 2023.
Post-announcement, many brokers formally moved to Neutral or Hold while keeping coverage open, explicitly because upside and downside are now mainly tied to deal execution. In practice, that means fewer fresh fundamental notes and more short commentaries focused on approvals and timing.
The business behind the numbers
ShockWave Medical develops and markets intravascular lithotripsy systems to treat calcified cardiovascular disease. The core idea is to use sonic pressure waves, delivered via a catheter-based balloon, to fracture calcified plaque and improve vessel compliance during angioplasty.
This niche has grown as physicians see heavily calcified lesions more often in an aging population with high cardiovascular risk. The company has argued that its technology can reduce procedural complications and improve stent expansion in difficult anatomy compared with conventional techniques.
Operational focus under an M&A umbrella
While the market waits for closing, ShockWave continues to emphasize global expansion and product iterations. Regulatory clearances in additional countries, along with new indications, have historically been key drivers of procedure volume and catheter sales.
Integration planning with Boston Scientific will likely prioritize maintaining physician adoption, securing supply chains for catheters and generators, and aligning commercial teams. However, neither company has given detailed integration guidance beyond standard synergy language at this stage.
What the company sells
ShockWave Medical’s flagship product family is the Shockwave IVL system, including catheters such as the Shockwave C2 for coronary applications and M5+ for peripheral arteries, plus dedicated generators that deliver the lithotripsy pulses in the catheter balloon.
Where the stock trades today
ShockWave Medical shares (US8130281086) last traded on Nasdaq at about $333.50 on 06/17/2026, 16:30 ET, slightly below the agreed $335 cash offer from Boston Scientific.
Key facts on ShockWave Medical stock
- Company: ShockWave Medical Inc.
- ISIN: US8130281086
- WKN: A2PNLV
- Ticker: SWAV
- Venue: Nasdaq
- Price (as of 06/17/2026, 16:30 ET): 333.50 USD
- Market cap: 12.6 billion USD (as of 06/17/2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
